Literature DB >> 16236046

Calcium antagonists and deep gingival pockets in the population-based SHIP study.

Peter Meisel1, Christian Schwahn, Ulrich John, Heyo K Kroemer, Thomas Kocher.   

Abstract

AIM: Gingival overgrowth is a common undesired side-effect in patients taking calcium channel blockers. Different reports have suggested that the drug-induced gingival hyperplasia may aggravate inflammatory periodontal disease. However, representative epidemiological data are lacking. We investigated the association between the intake of calcium antagonists and periodontitis in a population-based analysis including the most important risk factors of periodontitis.
METHODS: In a cross-sectional epidemiological investigation involving 4290 subjects aged 20-80 years, we recorded periodontal risk factors and identified participants using calcium antagonists. Periodontal parameters, attachment loss, probing depth and number of teeth were assessed. In a subgroup analysis with matched pairs, 456 subjects using calcium antagonists and 456 without were compared for periodontal status.
RESULTS: Subjects treated with calcium antagonistic drugs had significantly deeper gingival pockets than their drug-free counterparts. This was observed in the total population of 4290 and confirmed by logistic regression analyses (P < 0.001) controlled for the known risk factors of periodontitis (age, sex, smoking, education). In the matched-pair analysis only the probing depth was increased: extent probing depth > or = 4 mm median 23.5 vs. 17.0% (P < 0.001); mean probing depth 3.0 +/- 0.8 vs. 2.7 +/- 0.9 mm (P < 0.001). No differences were found in extent and severity of clinical attachment loss and in the number of teeth. The risk of gingival overgrowth was aggravated in smokers.
CONCLUSION: In the general population, treatment with calcium antagonists leads to gingival overgrowth without an aggravation of periodontal disease. Interaction with smoking indicates the multifactorial background of the undesired effect of calcium antagonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236046      PMCID: PMC1884946          DOI: 10.1111/j.1365-2125.2005.02485.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Smoking influences on the thickness of marginal gingival epithelium.

Authors:  Cristina Cunha Villar; Antonio Fernando de Lima
Journal:  Pesqui Odontol Bras       Date:  2003-08-05

2.  Study of Health in Pomerania (SHIP): a health survey in an East German region. Objectives and design of the oral health section.

Authors:  Elke Hensel; Dietmar Gesch; Reiner Biffar; Olaf Bernhardt; Thomas Kocher; Christian Splieth; Gabriele Born; Ulrich John
Journal:  Quintessence Int       Date:  2003-05       Impact factor: 1.677

3.  Influence of cigarette smoking on vascular reaction during experimental gingivitis.

Authors:  J Bergström; L Persson; H Preber
Journal:  Scand J Dent Res       Date:  1988-02

4.  Cyclosporin, nifedipine, and gingival hyperplasia.

Authors:  J Slavin; J Taylor
Journal:  Lancet       Date:  1987-09-26       Impact factor: 79.321

5.  Clinical assessment of gingival size among patients treated with diltiazem.

Authors:  P Bullon; G Machuca; A Martinez Sahuquillo; J Rojas; J R Lacalle; J V Rios; E Velasco
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1995-03

Review 6.  The pathogenesis of drug-induced gingival overgrowth.

Authors:  R A Seymour; J M Thomason; J S Ellis
Journal:  J Clin Periodontol       Date:  1996-03       Impact factor: 8.728

7.  Incidence of verapamil-induced gingival hyperplasia in a dental population.

Authors:  C S Miller; D D Damm
Journal:  J Periodontol       Date:  1992-05       Impact factor: 6.993

8.  The effect of basic fibroblast growth factor on cell cycle in human gingival fibroblasts from nifedipine responder and non-responder.

Authors:  Reiri Takeuchi
Journal:  J Oral Sci       Date:  2004-03       Impact factor: 1.556

9.  Gingival hyperplasia caused by nifedipine--a preliminary report.

Authors:  Y Ramon; S Behar; Y Kishon; I S Engelberg
Journal:  Int J Cardiol       Date:  1984-02       Impact factor: 4.164

Review 10.  Connective tissue metabolism and gingival overgrowth.

Authors:  P C Trackman; A Kantarci
Journal:  Crit Rev Oral Biol Med       Date:  2004-06-04
View more
  6 in total

1.  Co2 laser treatment of drug-induced gingival overgrowth - case report -.

Authors:  Carlo Fornaini; Jean Paul Rocca
Journal:  Laser Ther       Date:  2012-03-28

Review 2.  Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis.

Authors:  R S Brown; P R Arany
Journal:  Oral Dis       Date:  2014-08-07       Impact factor: 3.511

3.  Combination of inflammatory and amlodipine induced gingival overgrowth in a patient with cardiovascular disease.

Authors:  Mohan Kumar Pasupuleti; S V V S Musalaiah; M Nagasree; P Aravind Kumar
Journal:  Avicenna J Med       Date:  2013-07

Review 4.  Drug-induced gingival overgrowth in cardiovascular patients.

Authors:  Lucija Bajkovec; Anna Mrzljak; Robert Likic; Ivan Alajbeg
Journal:  World J Cardiol       Date:  2021-04-26

Review 5.  Gingival fibromatosis: clinical, molecular and therapeutic issues.

Authors:  Katarzyna Gawron; Katarzyna Łazarz-Bartyzel; Jan Potempa; Maria Chomyszyn-Gajewska
Journal:  Orphanet J Rare Dis       Date:  2016-01-27       Impact factor: 4.123

Review 6.  Is dental plaque the only etiological factor in Amlodipine induced gingival overgrowth? A systematic review of evidence.

Authors:  Sumit Gaur; Rupali Agnihotri
Journal:  J Clin Exp Dent       Date:  2018-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.